Calcium Antagonists Prevent Monocyte and Endothelial Cell-Induced Modification of Low Density Lipoproteins

References

• Brown M.S., Goldstein J.L. Receptor-mediated control of cholesterol metabolism. Science 1976; 191: 150–154
   PubMed Web of Science ®Google Scholar
• Brown M.S., Kovanen P.T., Goldstein J.L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212: 628–635
   PubMed Web of Science ®Google Scholar
• Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of LDL previously incubated with cultured endothelial cells: recognition by receptors for acetylated LDL. Proceedings of the National Academy of Science, USA 1981; 78: 6499–6503
   PubMed Web of Science ®Google Scholar
• Morel D.W., Di Corletto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984; 4: 357–364
   PubMedGoogle Scholar
• Heinecke J.W., Rosen H., Chait A. Iron and copper promote modification of low density lipoprotein by human arterial muscle cells in culture. Journal of Clinical Investigation 1984; 74: 1890–1894
   PubMed Web of Science ®Google Scholar
• Cathcart M.K., Morel D.W., Chisolm G.M. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. Journal of Leukocytes in Biology 1985; 38: 341–350
   PubMed Web of Science ®Google Scholar
• Leake D.S., Rankin S.M. The oxidative modification of low density lipoproteins by macrophages. Biochemical Journal 1990; 270: 741–748
   PubMed Web of Science ®Google Scholar
• Steinberg D. Metabolism of lipoproteins and their role in the pathogenesis of atherosclerosis. Atherosclerosis Review 1988; 18: 1–23
   Google Scholar
• Steinbrecher U.P. Role of oxidatively modified LDL in atherosclerosis. Free Rudicals in Biological Medicine, 9: 155–168
   Google Scholar
• Boyd H.C., Gown A.M., Wolfbauer G., Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanable heritable hyperlipidemic rabbit. American Journal of Pathology 1989; 135: 815–825
   PubMed Web of Science ®Google Scholar
• Parthasardty S., Young S.G., Witztum J.L., Pittman R.C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. Proceedings of the National Academy of Science, USA 1985; 77: 135–143
   Google Scholar
• Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proceedings of the Nutional Academy. of Science, USA 1987; 84: 5928–5931
   PubMed Web of Science ®Google Scholar
• Daugherty A., Zweifel B.S., Schonfield G.S. Probucol attenuates the development of atherosclerosis in cholesterol-fed rabbits. British Journal of Pharmacology, 98: 612–618
   PubMedGoogle Scholar
• Breugnot C., Maziere C., Salmon S., Auclair M., Santus R., Morlière P., Lenaers A., Mazière J.C. Phenothiazines inhibit copper and endothelial cell-induced peroxidation of low density lipoprotein. Biochemical Pharmacology 1990; 40: 1975–1980
   PubMed Web of Science ®Google Scholar
• Nayler W.G., Panagiotopoulos S., Elz J.S., Sturrock W.J. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. American Journal of Cardiology 1987; 59: 75B–83B
   Google Scholar
• Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line. International Journal of Cancer 1976; 17: 565–577
   PubMed Web of Science ®Google Scholar
• Ralph P., Pritchard J., Cohn M. Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. Journal of Immunology 1975; 114: 898–908
   PubMed Web of Science ®Google Scholar
• Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. Journal of Clinical Investigation. 1973; 52: 2745–2756
   PubMed Web of Science ®Google Scholar
• Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 1955; 34: 1345–1353
   PubMed Web of Science ®Google Scholar
• Bilheimer D.W., Eisenberg S., Levy R.I. The metabolism of very low density lipoproteins. I. Preliminary in vivo and in vitro observations. Biochimica et Biophysica Acta 1972; 260: 212–221
   PubMed Web of Science ®Google Scholar
• Yagi K. Lipid peroxides and human diseases. Chemistry and Physics of Lipids 1987; 45: 337–351
   PubMed Web of Science ®Google Scholar
• Laurman W., Salmon S., Mazitre C., Mazière J.C., Auclair M., Theron L., Santus R. Carbon disulfide modification and impaired catabolism of low density lipoprotein. Atherosclerosis 1989; 78: 221–218
   Google Scholar
• Blois M.S. Antioxidant determinations by the use of a stable free radical. Nature 1958; 181: 1199–1200
   Web of Science ®Google Scholar
• Ondrias K., Misik V., Gergel D., Stasko A. Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrythmic-antihypoxic drug stobadine. Biochimica et Biophysica Acta 1989; 1003: 238–245
   PubMed Web of Science ®Google Scholar
• Janero D.R., Burghardt B., Lopez R. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochemical Pharmacology 1988; 37: 4197–3203
   PubMed Web of Science ®Google Scholar
• Janero D.R., Burghardt D. Antiperoxidant effects of dihydropyridine calcium antagonists. Biochemical Pharmacology 1989; 38: 4344–4348
   PubMed Web of Science ®Google Scholar
• Nagatsuka S., Nakazawa T. Effects of membrane-stabilizing agents, cholesterol and cepharantin, on radiation-induced lipid peroxidation and permeability in liposomes. Biochimica et Biophysica Acta 1982; 691: 171–177
   Google Scholar
• McLean L.R., Hagaman K.A. Antioxidant activity of probucol and its effects on phase transitions in phosphatidylcholine liposomes. Biochimica et Biophysica Acta 1990; 1029: 161–166
   PubMedGoogle Scholar
• Rouleau J.L., Parmley W.W., Stevens J., Wikman-Coffelt J., Sievers R., Mahley R.W., Havel R.J. Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. Journal of the American College of Cardiology 1983; 1: 1453–1460
   PubMed Web of Science ®Google Scholar
• Sugano M., Nakashima Y., Matsuhima T., Takahara K., Takasugi M., Kuroiwa A., Koide O. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection. Arteriosclerosis 1986; 6: 237–241
   PubMedGoogle Scholar
• Stein O., Leitersdorf E., Stein Y. Verapamil enhances receptor-mediated endocytosis of low density lipoproteins by aortic cells in culture. Arteriosclerosis 1985; 5: 35–44
   PubMedGoogle Scholar
• Corsini A., Granata A., Fumagalli R., Paoletti R. Calcium antagonists and low density lipoprotein metabolism by human fibroblasts and hepatoma cell line Hep G2. Pharmacological Research Communications 1986; 18: 1–16
   PubMedGoogle Scholar
• Candide C., Mazière J.C., Mazière C., Lageron A., Polonovski J. The effects of perhexiline maleate on low density lipoprotein processing and cholesterol metabolism in cultured human fibroblasts. European Journal of Clinical Pharmacology 1988; 34: 195–199
   PubMedGoogle Scholar
• Chappey-Gillet B., Salmon S., Mazière C., Auclair M., Mazière J.C. Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol. Biochimica et Biophysica Acta 1990; 1052: 213–277
   Google Scholar
• Schmitz G., Robenek H., Beuck M., Krause R., Schurek A., Niemann R. Ca2+ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis 1988; 8: 46–56
   PubMedGoogle Scholar